Neurocentrx Pharma Ltd

Bexson Biomedical

This biopharmaceutical company develops subcutaneous ketamine delivery technologies and wearable devices to treat patients with chronic pain and mental health conditions.

Beckley Psytech

The company develops psychedelic-derived medicines to treat patients with neurological and psychiatric conditions such as treatment-resistant depression and rare headache disorders.

Cyclerion Therapeutics

This biopharmaceutical company develops neuropsychiatric therapies for patients with treatment-resistant depression and other neurodegenerative diseases.

Kasvu Therapeutics

This company develops small-molecule neuroplastogen treatments for neuropsychiatric and neurodegenerative disorders, targeting patients with major depressive disorder and brain diseases.

Delix

This company develops non-hallucinogenic neuroplasticity-promoting medicines to treat neuropsychiatric and neurodegenerative conditions for patients with brain disorders.

Freedom Biosciences

The company develops ketamine and psychedelic therapeutics for patients suffering from treatment-resistant depression and other mental health conditions.

Draig Therapeutics

The company develops neuromodulators and receptor potentiators for patients with major depressive disorder and other neuropsychiatric conditions.

Neurosterix

This biopharmaceutical company develops allosteric modulator therapeutics to treat patients suffering from neurological and neuropsychiatric disorders, including schizophrenia and mood disorders.